The customary approach to early-phase clinical trial design, where the focus is on identification of the maximum tolerated dose, is not always suitable for noncytotoxic or other targeted therapies.
Vol. 26, No. 3, Special Issue on the Symposium on Statistics and the Sciences / Numéro spécial consacré au symposium sur la statistique et les sciences (Sep., 1998), pp. 479-495 (17 pages) Consider ...
Lyric Semiconductor thinks it is probably time to blend analog and digital technology into a new technology they call probability processing. Analog values called pbits that are processed by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback